Shiv Srivastava

OverviewAI-generated summary

Shiv Srivastava's research focuses on the molecular mechanisms and genetic underpinnings of prostate cancer, with a particular emphasis on disparities affecting men of African ancestry. His work has investigated novel susceptibility variants for prostate cancer and the development of multiancestry polygenic risk scores to identify aggressive disease in specific populations. Srivastava has also explored prognostic indicators within prostate tumors, including focal p53 protein expression and lymphovascular invasion, and the utility of multiparametric MRI and immunohistochemistry in predicting biochemical recurrence following radical prostatectomy.

His research extends to identifying potentially targetable genetic alterations in prostate cancer, such as germline mutations in DNA damage repair genes, and the development of novel therapeutic strategies, including selective inhibitors for ERG-positive prostate cancer. Srivastava's publications also delve into fundamental cellular processes, such as the structural basis of apoptosis regulation through protein interactions like BAK sequestration by MCL-1 and the inhibition of BAK-mediated apoptosis by BNIP5. His scholarship metrics include an h-index of 64, with over 490 publications and 14,961 citations, reflecting his significant contributions to the field. Key collaborators include Bin Dong and Meek Yang from the University of Arkansas at Fayetteville, and Elisabeth Ferreira from the University of Arkansas for Medical Sciences.

Metrics

• h-index: 64
• Publications: 490
• Citations: 14,961